| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Response to Sung, Rosenberg, and Yang
|
Lin C.-H.; Yap Y.S.; Lee K.-H.; Yeo W.; Ueno T.; Li H.; Huang S.-M.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Chih-Hung Hsu;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chih-Hung Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIH-HUNG HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-01-04T07:41:13Z |
Giardiasis with malabsorption syndrome: report of one case
|
Hsu J.Y.; Wang J.K.; MEI-HWEI CHANG; Wang J.K.;Mei-Hwei Chang;Hsu J.Y.;Lee K.H.;Hsu H.C.; Lee K.H.; Hsu H.C. |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 國立成功大學 |
2021 |
Colorectal cancer stage-specific fecal bacterial community fingerprinting of the taiwanese population and underpinning of potential taxonomic biomarkers
|
Fang, C.-Y.;Chen, J.-S.;Hsu, B.-M.;Hussain, B.;Rathod, J.;Lee, K.-H. |
| 國立成功大學 |
2021 |
Spin wave excitations in honeycomb antiferromagnet MnTiO3
|
Hwang, I.Y.;Lee, K.H.;Chung, J.-H.;Ikeuchi, K.;Garlea, V.O.;Yamauchi, H.;Akatsu, M.;Shamoto, Shamoto S.-I. |
| 臺大學術典藏 |
2020-12-28T05:56:09Z |
A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways
|
Guh J.-H.; Bastow K.F.; Lee K.-H.; Nakagawa-Goto K.; Yu C.-C.; Chiang P.-C.; TING-CHUN KUO |
| 臺大學術典藏 |
2020-12-23T02:57:18Z |
Nationwide epidemiology and prognosis of dialysis-requiring acute kidney injury (NEP-AKI-D) study: Design and methods
|
Weng C.-J.; Tsai J.-P.; You Z.-H.; Chen C.-M.; Kuo F.-C.; Lin H.Y.-H.; Kan W.-C.; Wang J.-J.; Chien K.-L.; Lu K.-C.; Liou H.-H.; Hu F.-C.; Chen T.-C.; Lin C.-Y.; Lee K.-H.; Huang C.-T.; Sun C.-Y.; Kao C.-C.; Shiao C.-C.; Wu P.-C.; VIN-CENT WU; Lin J.-H.; Pan H.-C.; Yang Y.-F.; Lai T.-S.; Huang T.-M.; Wu C.-H.; Yang W.-S.; Wu C.-J.; Chen H.-Y.; Chang C.-F.; Hsu W.-D.; Wu M.-S.; Huang C.-C.; Wu K.-D.; on behalf of the Taiwan Consortium for Acute Kidney Injury Renal Diseases (CAKs) |
| 臺大學術典藏 |
2020-12-02T02:34:26Z |
Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-κB pathways
|
Lin J.-C.; Yang S.-C.; Hong T.-M.; Yu S.-L.; Qian S.; Linyi W.; Chen H.-Y.; Pan-Chyr Yang; Lee K.-H.; Lin J.-C.; Yang S.-C.; Hong T.-M.; Yu S.-L.; Qian S.; Linyi W.; Chen H.-Y.; PAN-CHYR YANG; Lee K.-H. |
| 臺大學術典藏 |
2020-12-02T02:34:23Z |
Antitumor agents 268. Design, synthesis, and mechanistic studies of new 9-substituted phenanthrene-based tylophorine analogues as potent cytotoxic agents
|
Yang X.; Shi Q.; Liu Y.-N.; Zhao G.; Bastow K.F.; Lin J.-C.; Yang S.-C.; Pan-Chyr Yang; Lee K.-H.; Yang X.; Shi Q.; Liu Y.-N.; Zhao G.; Bastow K.F.; Lin J.-C.; Yang S.-C.; PAN-CHYR YANG; Lee K.-H. |
| 臺大學術典藏 |
2020-12-02T02:33:57Z |
Antitumor agents 295. E-ring hydroxylated antofine and cryptopleurine analogues as antiproliferative agents: Design, synthesis, and mechanistic studies
|
Yang X.; Shi Q.; Lai C.-Y.; Chen C.-Y.; Ohkoshi E.; Yang S.-C.; Wang C.-Y.; Bastow K.F.; Wu T.-S.; Pan S.-L.; Teng C.-M.; Pan-Chyr Yang; Lee K.-H.; Yang X.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:47Z |
Depletion of 4E-BP1 and regulation of autophagy lead to YXM110-induced anticancer effects
|
Lai C.-Y.; Pan S.-L.; Yang X.-M.; Chang L.-H.; Chang Y.-L.; PAN-CHYR YANG; Lee K.-H.; Teng C.-M.; Lai C.-Y.; Pan S.-L.; Yang X.-M.; Chang L.-H.; Chang Y.-L.; PAN-CHYR YANG; Lee K.-H.; Teng C.-M. |
| 臺大學術典藏 |
2020-12-02T02:33:42Z |
The antitumor agent PBT-1 directly targets HSP90 and hnRNP A2/B1 and inhibits lung adenocarcinoma growth and metastasis
|
Chen C.-Y.;Yang S.-C.;Lee K.-H.;Yang X.;Wei L.-Y.;Chow L.-P.;Wang T.-C.V.;Hong T.-M.;Lin J.-C.;Kuan C.;PAN-CHYR YANG; Chen C.-Y.; Yang S.-C.; Lee K.-H.; Yang X.; Wei L.-Y.; Chow L.-P.; Wang T.-C.V.; Hong T.-M.; Lin J.-C.; Kuan C.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:33:31Z |
Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects
|
PAN-CHYR YANG et al.; Wada K.; Wada K.; Lee J.-Y.; Hung H.-Y.; Shi Q.; Lin L.; Zhao Y.; Goto M.; Pan-Chyr Yang; Kuo S.-C.; Chen H.-W.; Lee K.-H. |
| 臺大學術典藏 |
2020-12-02T02:33:07Z |
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer
|
Chen Z.; Huang K.-Y.; Ling Y.; Goto M.; Duan H.-Q.; Tong X.-H.; Liu Y.-L.; Cheng Y.-Y.; Morris-Natschke S.L.; Pan-Chyr Yang; Yang S.-L.; Lee K.-H.; Chen Z.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-09-28T07:04:37Z |
Nationwide epidemiology and prognosis of dialysis-requiring acute kidney injury (NEP-AKI-D) study: Design and methods
|
Lee K.-H.; Huang C.-T.; Shiao C.-C.; Wu P.-C.; Lin J.-H.; Pan H.-C.; Yang Y.-F.; Lai T.-S.; Huang T.-M.; Wu C.-H.; Yang W.-S.; Wu C.-J.; Kao C.-C.; Sun C.-Y.; Lin C.-Y.; Chen T.-C.; Hu F.-C.; Liou H.-H.; Lu K.-C.; Chien K.-L.; Wang J.-J.; Kan W.-C.; Kuo F.-C.; Lin H.Y.-H.; Chen C.-M.; You Z.-H.; Tsai J.-P.; Weng C.-J.; Chen H.-Y.; Chang C.-F.; Hsu W.-D.; Wu M.-S.; Huang C.-C.; Wu K.-D.; on behalf of the Taiwan Consortium for Acute Kidney Injury Renal Diseases (CAKs) |
| 臺大學術典藏 |
2020-06-27T06:40:12Z |
Reduction of human-to-pig cellular response by alteration of porcine MHC with human HLA DPW0401 exogenes
|
Lee J.-M.;Tu C.-F.;Yang P.-W.;Lee K.-H.;Tsuji K.;Tsai M.-K.;Chen R.J.;Hu C.-Y.;Hsieh R.-P.;Tai H.-C.;Bor-Luen Chiang;Weng C.-N.;Lee Y.-C.;Lee C.-J.; Lee J.-M.; Tu C.-F.; Yang P.-W.; Lee K.-H.; Tsuji K.; Tsai M.-K.; Chen R.J.; Hu C.-Y.; Hsieh R.-P.; Tai H.-C.; BOR-LUEN CHIANG; Weng C.-N.; Lee Y.-C.; Lee C.-J. |
| 臺大學術典藏 |
2020-06-17T03:01:51Z |
Antitumor agents 283. Further elaboration of Desmosdumotin C analogs as potent antitumor agents: Activation of spindle assembly checkpoint as possible mode of action
|
Nakagawa-Goto K. ;Wu P.-C. ;Bastow K.F. ;Yang S.-C. ;Sung-Liang Yu ;Chen H.-Y. ;Lin J.-C. ;Goto M. ;Morris-Natschke S.L. ;Yang P.-C. ;Lee K.-H.; Nakagawa-Goto K.; Wu P.-C.; Bastow K.F.; Yang S.-C.; SUNG-LIANG YU; Chen H.-Y.; Lin J.-C.; Goto M.; Morris-Natschke S.L.; Yang P.-C.; Lee K.-H. |
| 臺大學術典藏 |
2020-06-17T03:01:50Z |
Antitumor agents 288: Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents
|
Yang X. ;Shi Q. ;Yang S.-C. ;Chen C.-Y. ;Sung-Liang Yu ;Bastow K.F. ;Morris-Natschke S.L. ;Wu P.-C. ;Lai C.-Y. ;Wu T.-S. ;Pan S.-L. ;Teng C.-M. ;Lin J.-C. ;Yang P.-C. ;Lee K.-H.; Yang X.; Shi Q.; Yang S.-C.; Chen C.-Y.; SUNG-LIANG YU; Bastow K.F.; Morris-Natschke S.L.; Wu P.-C.; Lai C.-Y.; Wu T.-S.; Pan S.-L.; Teng C.-M.; Lin J.-C.; Yang P.-C.; Lee K.-H. |
| 臺大學術典藏 |
2020-06-17T03:00:43Z |
Reduction of human-to-pig cellular response by alteration of porcine MHC with human HLA DPW0401 exogenes
|
Lee J.-M.;Tu C.-F.;Yang P.-W.;Lee K.-H.;Tsuji K.;Tsai M.-K.;Chen R.J.;Hu C.-Y.;Hsieh R.-P.;Hao-Chih Tai;Chiang B.-L.;Weng C.-N.;Lee Y.-C.;Lee C.-J.; Lee J.-M.; Tu C.-F.; Yang P.-W.; Lee K.-H.; Tsuji K.; Tsai M.-K.; Chen R.J.; Hu C.-Y.; Hsieh R.-P.; HAO-CHIH TAI; Chiang B.-L.; Weng C.-N.; Lee Y.-C.; Lee C.-J. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
|
Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
